DUBLIN, Feb. 3, 2017 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today provided an update on its Board of Directors and
set the record date and the meeting date for its 2017 Annual
General Meeting of Shareholders.
Allergan's Board of Directors elected Adriane M. Brown as a new director. The Company
had previously announced that Brown would join the Board beginning
in February 2017. Ms. Brown is
currently President and Chief Operating Officer of Intellectual
Ventures LLC, a private global invention company focused on
providing access to valuable patents and invention related
services. Ms. Brown has served on the Board of Directors of Harman
International Industries, Inc. since June
2013, where she is a member of the Compensation Committee
and the Technology and Innovation Committee.
"Adriane's 30-year track record of management leadership and
public board experience make her an exceptional fit to support
Allergan's focus on innovation and growth," said Brent Saunders, Chairman, CEO and President of
Allergan.
Separately, Allergan announced that Michael R. Gallagher will be retiring from its
Board of Directors, and therefore will not stand for re-election at
the 2017 Annual General Meeting of Shareholders. Gallagher has
served as a director since March
2015. He previously served on the Allergan, Inc. Board of
Directors from 1998 until Allergan, Inc. was acquired by Actavis
plc. In 2004, Mr. Gallagher retired as Chief Executive Officer and
as a Director of Playtex Products, Inc.
"We thank Mike for his tremendous service and commitment to
Allergan over the course of nearly two decades. During that time
Allergan experienced significant growth and was transformed into a
leading biopharmaceutical company. We wish him and his family all
the best in his retirement," said Saunders.
Allergan also announced that its 2017 Annual General Meeting of
Shareholders will be held on May 4,
2017 in Dublin, Ireland.
The Company also announced that its Board of Directors has set the
close of business on March 8, 2017 as
the record date for determining shareholders eligible to vote at
the meeting.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing, manufacturing and
commercializing branded pharmaceuticals, devices and biologic
products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the
Company's R&D model, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. This approach has led to Allergan building one
of the broadest development pipelines in the pharmaceutical
industry with 70+ mid-to-late stage pipeline programs in
development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2015 and Quarterly Report on Form 10-Q for the quarter ended
September 30, 2016. Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Mark
Marmur
|
|
(862)
261-7558
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-provides-board-and-annual-shareholder-meeting-updates-300401791.html
SOURCE Allergan plc